Skip to content

Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease

Transcranial Magnetic Stimulation (TMS) in Patients With Mild Cognitive Impairment (MCI) and Alzheimer Disease (AD): A Twelve-year Retrospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04771845
Enrollment
73
Registered
2021-02-25
Start date
2008-05-01
Completion date
2020-05-30
Last updated
2021-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Mild Cognitive Impairment

Keywords

TMS, Transcranial Magnetic Stimulation

Brief summary

The investigators reviewed 12 years of clinical use in an outpatient neurology setting of transcranial magnetic stimulation (TMS) in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) to evaluate safety and efficacy of TMS.

Detailed description

The investigators compiled demographic, clinical, and neurocognitive data on all patients who had received TMS for any reason in the clinic over a 12-year period. Of 236 patients receiving TMS, 59 patients with AD and 14 with MCI satisfied study criteria and were compared to controls from the National Alzheimer's Coordinating Center (NACC). Neurocognitive outcomes were compared between magnetic resonance imaging (MRI) and electroencephalogram (EEG)-grid guided TMS in patients. Tolerability data was reviewed for all patients.

Interventions

DEVICETranscranial Magnetic Stimulation

Magnetic stimulation to alter neural activity

Sponsors

The New York Memory Services
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients meeting the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) criteria for possible or probable Alzheimer's disease. * Patients meeting the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) criteria for mild cognitive impairment. * Patients must have undergone at least two standardized neurocognitive batteries before and after beginning TMS. * Patients must have received greater than or equal to five (5) TMS sessions in less than one year.

Exclusion criteria

• Patients with dementias from other causes, such as Lewy Body disease.

Design outcomes

Primary

MeasureTime frameDescription
Controlled Oral Word Association Test05/01/2008-05/30/2020Animal score and percentile
Boston 30-item naming test05/01/2008-05/30/2020spontaneous correct (without cues)
Wechsler Adult Intelligence Scale III05/01/2008-05/30/2020Digit span
Wechsler Memory Scale III05/01/2008-05/30/2020Immediate memory score and percentile
Buschke Selective Reminding Test, 12 item05/01/2008-05/30/2020Total recall score
Buschke Selective Reminding Test, 12 item, 15 minute05/01/2008-05/30/2020Delayed recall score
Rosen Drawing Test05/01/2008-05/30/2020Total score
Processing speed05/01/2008-05/30/2020Total score and percentile
Mini-mental status examination05/01/2008-05/30/2020Total score

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026